• Our Science

    Programs developing molecules to amplify immune recognition of cancers

  • Clinical Trials

    Targeting various cancers either in monotherapy or in combination

  • Working at iTeos

    Recruiting top talent for both our US and Belgium sites

Pipeline

iTeos focuses upon selected key mechanisms by which cancer cells suppress the immune system.

The identification of these mechanisms is based on gene expression profiles of immune cell subsets as they recognize tumor cell targets, protein expression in human tumors and demonstration of proof of concept by blocking these mechanisms in a variety of laboratory models.

Learn more about our pipeline
Program Trial Design Indications Preclinical Phase 1 Phase 1b/2a Phase 2/3
Inupadenant
Monotherapy Solid tumors
+ pembrolizumab Anti-PD-1-Resistant Melanoma
+ pembrolizumab Castrate-Resistant Prostate Cancer
+ paclitaxel carboplatin Triple-Negative Breast Cancer
EOS-448
Dose Finding, PK/PD Solid tumors
+ IMID Multiple Myeloma
+ pembrolizumab Solid Tumors
+ Inupadenant Solid Tumors
Adenosine Pathway Inhibitor
Oncology

Our latest news

  • iTeos Therapeutics Announces New Preliminary Data Indicating Clinical Activity with its Anti-TIGIT Antibody, EOS-448, at the AACR Annual Meeting 2021

    Initial data from the Phase 1 dose escalation part of the Phase 1/2a trial in adult patients with advanced solid tumors indicated EOS-448 was generally well tolerated with no dose-limiting toxicities observed EOS-448 showed preliminary signs of clinical activity as a monotherapy, including a

  • iTeos Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

    – Initial data from Phase 1/2a trial of EOS-448 to be presented at American Association for Cancer Research Annual Meeting. Company to hold conference call at 8:00 am on April 12 th to discuss results – – Updated, single-agent data of inupadenant (EOS-850) from Phase 1/2a trial and initial

  • iTeos to Present at Upcoming Investor Conferences in March

    CAMBRIDGE, Mass. and GOSSELIES, Belgium, Feb. 23, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today

  • iTeos to Present at the 10th Annual SVB Leerink Global Healthcare Conference

    CAMBRIDGE, Mass. and GOSSELIES, Belgium, Feb. 17, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today

  • iTeos to Present at the 39th Annual J.P. Morgan Healthcare Conference

    CAMBRIDGE, Mass. and GOSSELIES, Belgium, Jan. 05, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today

  • iTeos to Present at Piper Sandler 32nd Annual Healthcare Conference

    CAMBRIDGE, Mass. and GOSSELIES, Belgium, Nov. 23, 2020 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today

  • iTeos Reports Third Quarter 2020 Financial Results and Provides Business Update

    - Patient enrol l ment in Phase 1/2 stud ies of EOS-850 A 2A R antagonist and EOS-448 FCγ R-enabled anti-TIGIT antibody continue s with initial data expected in 1H21 -  - Strong cash position to support ongoing clinical development and operations into 2023 - CAMBRIDGE, Mass.

  • iTeos Appoints Matthew Roden, Ph.D. to Board of Directors

    CAMBRIDGE, Mass. and GOSSELIES, Belgium, Nov. 12, 2020 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today

  • iTeos to Participate in Upcoming Investor Conferences in November

    CAMBRIDGE, Mass. and GOSSELIES, Belgium, Nov. 05, 2020 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today